766 million lives were touched by Novartis medicines in 2021, and while we're proud of this, we know there is so much more we could do to help improve and extend people's lives. We believe new insights, perspectives and ground breaking solutions can be found at the intersection of medical science and digital innovation. That a diverse, equitable and inclusive environment

100,000 and more! That's how many patients are treated in our studies. And every year, 3 million documents are uploaded in the electronic Trial Master Files to preserve the story of the study and ensure innovative medicines can reach even more patients worldwide. But in this world of digital and technological transformation, we must also continue to evolve our approaches

100,000 and more! That's how many patients are treated in our studies. And every year, 3 million documents are uploaded in the electronic Trial Master Files to preserve the story of the study and ensure innovative medicines can reach even more patients worldwide. But in this world of digital and technological transformation, we must also continue to evolve our approaches

By 2023, Patient and Specialty Services (PSS) is projected to support over 1.4 Million patients and impact nearly $4B of Novartis's US Pharma revenue. PSS provides mission critical support to Novartis brands by helping patients access medications needed to improve their health. The creation of an internal Engagement Center is a strategic priority for US Pharma. We have an

766 million lives were touched by Novartis medicines in 2021, and while we're proud of this, we know there is so much more we could do to help improve and extend people's lives. We believe new insights, perspectives and ground breaking solutions can be found at the intersection of medical science and digital innovation. That a diverse, equitable and inclusive environment

Cardio metabolic disease is the leading cause of death worldwide, taking an estimated 17.9 million lives each year. Obesity not only directly contributes to risk factors such as dyslipidemia and type 2 diabetes but also leads to the development of cardiovascular disease mortality independent of other risk factors. The Cardiovascular and Metabolic (CVM) Disease Area at the

766 million lives were touched by Novartis medicines in 2021, and while we're proud of this, we know there is so much more we could do to help improve and extend people's lives. Bringing life changing medicines to millions of people, Novartis sits at the intersection of cutting edge medical science and innovative digital technology. As a global company, the resources and

1 purpose! Novartis expands its early development and innovative CAR T cell therapy manufacturing capabilities in its newly launched Center of Excellence, located in the East Hanover, NJ campus. Our therapies are being developed as transformative treatments with life saving potential for various B cell malignancies and other oncological diseases. We look to be bold with p

1 purpose...to reimagine medicine! The Oncology Translational Research group at NIBR is recruiting a research oriented pathologist to provide scientific and clinical expertise to inform patient selection strategies and biomarker development. You will partner across the full range of Oncology programs (small molecules, biotherapeutics, radioligand therapies, and Immuno Onc

Cardio metabolic diseases result in the loss of about 17.9 million lives each year. The Cardiovascular and Metabolic Disease Area (CVM) of the Novartis Institutes for Biomedical Research (NIBR) is committed to changing this alarming statistic by discovering transformative medicines to treat cardiovascular and metabolic disorders. As Associate Director, Global Program Mana

1,800+ associates. 86 countries. One Regulatory Affairs. At Novartis your voice, experience, and quality mindset can truly make a difference in Regulatory Affairs (RA). Novartis has a unique and promising portfolio with 70 projects as potential NMEs in development, 65 projects in Phase 3 or already undergoing registration, and 100 Phase 1/2 projects. We also focus on rare

6000! This is the number of associates in the Novartis Institutes for BioMedical Research (NIBR). This division is the innovation engine of Novartis, focusing on new technologies that have the potential to help produce therapeutic breakthroughs for patients. The Biotherapeutic Engineering and Gene Therapy (BEGT) group is a part of the NIBR Biologics Center (NBC). BEGT dri

Your responsibilities include, but are not limited to Design and execution of pre clinical in vivo studies to explore novel hypotheses, evaluate candidate molecules, establish proof of concept, and investigate mechanism of action Develop in vivo CDX, PDX, and syngeneic models to evaluate anti tumor activity, PK/PD relationships, and relevant biomarkers of novel compounds

766 million lives were touched by Novartis medicines in 2021, and while we're proud of this, we know there is so much more we could do to help improve and extend people's lives. We believe new insights, perspectives and ground breaking solutions can be found at the intersection of medical science and digital innovation. That a diverse, equitable and inclusive environment

766 million lives were touched by Novartis medicines in 2021, and while we're proud of this, we know there is so much more we could do to help improve and extend people's lives. We believe new insights, perspectives and ground breaking solutions can be found at the intersection of medical science and digital innovation. That a diverse, equitable and inclusive environment